Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Although statins are widely prescribed medications, there remains considerable variability in therapeutic response. Genetics can explain only part of this variability. Metabolomics is a global biochemical approach that provides powerful tools for mapping pathways implicated in disease and in response to treatment. Metabolomics captures net interactions between genome, microbiome and the environment. In this study, we used a targeted GC-MS metabolomics platform to measure a panel of metabolites within cholesterol synthesis, dietary sterol absorption, and bile acid formation to determine metabolite signatures that may predict variation in statin LDL-C lowering efficacy. Measurements were performed in two subsets of the total study population in the Cholesterol and Pharmacogenetics (CAP) study: Full Range of Response (FR), and Good and Poor Responders (GPR) were 100 individuals randomly selected from across the entire range of LDL-C responses in CAP. GPR were 48 individuals, 24 each from the top and bottom 10% of the LDL-C response distribution matched for body mass index, race, and gender. We identified three secondary, bacterial-derived bile acids that contribute to predicting the magnitude of statin-induced LDL-C lowering in good responders. Bile acids and statins share transporters in the liver and intestine; we observed that increased plasma concentration of simvastatin positively correlates with higher levels of several secondary bile acids. Genetic analysis of these subjects identified associations between levels of seven bile acids and a single nucleotide polymorphism (SNP), rs4149056, in the gene encoding the organic anion transporter SLCO1B1. These findings, along with recently published results that the gut microbiome plays an important role in cardiovascular disease, indicate that interactions between genome, gut microbiome and environmental influences should be considered in the study and management of cardiovascular disease. Metabolic profiles could provide valuable information about treatment outcomes and could contribute to a more personalized approach to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Active cholesterol metabolites are produced by interspecies biosynthetic pathways. Bile acids are the main metabolites of cholesterol (CHOL). Primary bile acids (blue ovals; cholic acid (CA) and chenodeoxycholic acid (CDCA)) are produced by endogenous enzymes in the liver and are modified by bacteria of the genus Clostridia colonizing the gut to form secondary bile acids (yellow ovals; lithocholic acid (LCA) and deoxycholic acid [18]). Arrows broken by double lines represent multiple enzymatic steps and only the genes encoding the rate limiting enzymes are listed. The bacterial operon baiABCDEFGHI encodes eight enzymes and a bile acid transporter that together form the pathway for synthesis of secondary bile acids. The amino acids glycine and taurine are conjugated to primary and secondary bile acids in the liver by the host encoded bile acid-CoA amino acid transferase (BAAT) to form tauro- and glycolithocholic acid (TLCA, GLCA) and tauro- and glycodeoxycholic acid (TDCA GDCA). Gut bacteria of genus Lactobacillus catalyze the conversion of cholesterol metabolites to coprostanol (COPR) and can limit the intestinal absorption of cholesterol.](https://figures.cochat.ai/paper-figures/9948cbeee5e94e979366d6651fafcaf5/enteric-microbiome-metabolites-correlate-with-response-to-simvastatin-treatment-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In humans, the response to simvastatin treatment (indicated by LDL cholesterol levels) is positively associated with the pretreatment levels of three microbiota-produced secondary bile acids: lithocholic acid, taurolithocholic acid and glycolithocholic acid.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597 · cited 4×
“recently have implicated enteric bacteria and phosphatidylcholine metabolism in the pathogenesis of cardiovascular disease [15].”
BackgroundInfluentialRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829 · cited 1×
“have suggested that probiotics, by altering intestinal microflora, can alter the enterohepatic circulation of secondary bile acids [36].”
BackgroundMetabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites
Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., & Siuzdak, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812874106 · Cited by 2,677 · cited 1×
“Metabolomics can capture a unique portrait of the state and changes of the gut microbiota by direct measurements of metabolite production [12,13,14].”
BackgroundSLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 1×
“The SLCO1B1 transporter is of particular interest because it is known to transport simvastatin from plasma into the liver, and SNP rs4149056 has been associated with statin-induced myopathy in individuals treated with high dose simvastatin [34].”
BackgroundXenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807 · cited 2×
“At the same time simvastatin and bile acids also regulate the expression of these transporters [28,30,31,32].”
BackgroundClayton, T. A., Baker, D., Lindon, J. C., Everett, J. R., & Nicholson, J. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904489106 · Cited by 765 · cited 4×
“It is becoming increasingly clear that gut microbial symbiots are critical for normal digestion and defense, and also play an important role in development of disease [15] and in metabolizing orally ingested therapeutics [12].”
BackgroundInfluentialGut microbiome-host interactions in health and disease
Kinross, J. M., Darzi, A. W., & Nicholson, J. K. (2011) · Genome Medicine · doi:10.1186/gm228 · Cited by 691 · cited 1×
“Metabolomics can capture a unique portrait of the state and changes of the gut microbiota by direct measurements of metabolite production [12,13,14].”
Background
Cited by
Nakatsuji, T., Chen, T. H., Narala, S., Chun, K. A., Two, A. M., Yun, T., Shafiq, F., Kotol, P. F., Bouslimani, A., Melnik, A. V., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4680 · Cited by 1,095
Statin Toxicity: Mechanistic Insights and Clinical Implications
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 757
Sequencing and beyond: integrating molecular 'omics' for microbial community profiling
Franzosa, E. A., Hsu, T., Sirota-Madi, A., Shafquat, A., Abu-Ali, G., Morgan, X. C., & Huttenhower, C. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3451 · Cited by 719
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717
Metabolomics enables precision medicine: “A White Paper, Community Perspective”
for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative, Beger, R. D., Dunn, W., Schmidt, M. A., Gross, S. S., Kirwan, J. A., Cascante, M., Brennan, L., Wishart, D. S., Oresic, M., et al. (2016) · Metabolomics · doi:10.1007/s11306-016-1094-6 · Cited by 592
Self-citationBile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders
Fiorucci, S., & Distrutti, E. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.09.001 · Cited by 539
Aguiar-Pulido, V., Huang, W., Suarez-Ulloa, V., Cickovski, T., Mathee, K., & Narasimhan, G. (2016) · Evolutionary Bioinformatics · doi:10.4137/ebo.s36436 · Cited by 499
Gut microbiota, a new frontier to understand traditional Chinese medicines
Feng, W., Ao, H., Peng, C., & Yan, D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.024 · Cited by 377
The influence of gut microbiota on drug metabolism and toxicity
Li, H., He, J., & Jia, W. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1121234 · Cited by 278
“investigated the correlation between baseline metabolites and therapeutic efficacy of simvastatin with targeted metabolomics.[73] Their data indicated that the baseline levels of several secondary bile acids, which are gut microbial-derived, could predict the magnitude of LDL-C lowering effect of simvastatin.”
BackgroundAgeing and gut microbes: Perspectives for health maintenance and longevity
Biagi, E., Candela, M., Turroni, S., Garagnani, P., Franceschi, C., & Brigidi, P. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.005 · Cited by 276
The gut microbiota: A treasure for human health
Li, D., Wang, P., Wang, P., Hu, X., & Chen, F. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.08.003 · Cited by 261
A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility
Wei, M., Huang, F., Zhao, L., Zhang, Y., Yang, W., Wang, S., Li, M., Han, X., Ge, K., Qu, C., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102766 · Cited by 253
“Furthermore, altered BA profiles were associated with cholesterol metabolism, as evidenced by the fact that some secondary BAs were positively correlated with plasma simvastatin concentration, predicting individual responses to statin treatment [45].”
BackgroundTaking it Personally: Personalized Utilization of the Human Microbiome in Health and Disease
Zmora, N., Zeevi, D., Korem, T., Segal, E., & Elinav, E. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2015.12.016 · Cited by 252
The influence of the gut microbiota on the bioavailability of oral drugs
Zhang, X., Han, Y., Huang, W., Jin, M., & Gao, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.013 · Cited by 242
Chen, S., Kong, H., Lu, X., Li, Y., Yin, P., Zeng, Z., & Xu, G. (2013) · Analytical Chemistry · doi:10.1021/ac4016787 · Cited by 235
Self-citationCarlström, M., & Larsson, S. C. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy014 · Cited by 233
“A metabolomics study by Kaddurah-Daouk et al suggested that differences in the gut bacteria might play an important role.(170) Exercise, stress levels, genetic predisposition, and environment are factors that define an individual’s gut microbiome, but the diet may also have a modulatory role.”
MethodThe promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217
Pharmacomicrobiomics: a novel route towards personalized medicine?
Doestzada, M., Vila, A. V., Zhernakova, A., Koonen, D. P. Y., Weersma, R. K., Touw, D. J., Kuipers, F., Wijmenga, C., & Fu, J. (2018) · Protein & Cell · doi:10.1007/s13238-018-0547-2 · Cited by 210
Dey, P. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104367 · Cited by 209
Lamichhane, S., Sen, P., Dickens, A. M., Orešič, M., & Bertram, H. C. (2018) · Methods · doi:10.1016/j.ymeth.2018.04.029 · Cited by 201
Worms need microbes too: microbiota, health and aging in Caenorhabditis elegans
Cabreiro, F., & Gems, D. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201100972 · Cited by 193
Pharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology
Kaddurah-Daouk, R., & Weinshilboum, R. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.217 · Cited by 188
Self-citationUtilization of the microbiome in personalized medicine
Ratiner, K., Ciocan, D., Abdeen, S. K., & Elinav, E. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00998-9 · Cited by 170
Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine
Kaddurah‐Daouk, R., Weinshilboum, R., & on behalf of the Pharmacometabolomics Research Network (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.134 · Cited by 160
“Cholesterol ester and phospholipid classes (lipidomics platform) and several secondary bile acids produced by gut microbiome (sterol bile acids platform) were correlated with treatment outcomes.(13,15,16) Using metabolomics data generated by a GCTOF platform (gas chromatography time-of-flight mass spectrometry),(14) o…”
BackgroundMethodSelf-citationMetatranscriptomics for the Human Microbiome and Microbial Community Functional Profiling
Zhang, Y., Thompson, K. N., Branck, T. A., Yan, Y., Nguyen, L. H., Franzosa, E. A., & Huttenhower, C. (2021) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-031121-103035 · Cited by 168
Gut microbiota modulates drug pharmacokinetics
Zhang, J., Zhang, J., & Wang, R. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1497647 · Cited by 150
Linking microbiota to human diseases: a systems biology perspective
Wu, H., Tremaroli, V., & Bäckhed, F. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.09.011 · Cited by 150
“Moreover, statins, which are the first-line treatment for the prevention of CVD, have been shown to have antimicrobial effects [88], and plasma levels of several secondary bile acids were associated with a good response to simvastatin treatment [89].”
BackgroundThe human microbiome and bile acid metabolism: Dysbiosis, dysmetabolism, disease and intervention
Jones, M. L., Martoni, C. J., Ganopolsky, J. G., Labbé, A., & Prakash, S. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.880420 · Cited by 150
“Finally, studies of responders and non-responders to statin therapy have shown that the transformation of BAs by the gut microbiota is associated with a response to statin therapy [88].”
BackgroundThe Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome.
Enright, E. F., Gahan, C. G. M., Joyce, S. A., & Griffin, B. T. (2016) · PubMed · Cited by 202
Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs
Feng, W., Liu, J., Ao, H., Yue, S., & Peng, C. (2020) · Theranostics · doi:10.7150/thno.47289 · Cited by 121
“acids derived from gut microbiota can contend with simvastatin for SLCO1B1 transporters, and correspondingly the plasma concentration and clinical efficacy of simvastatin are affected [31].”
BackgroundInfluentialMetagenome and metabolism: the tissue microbiota hypothesis
Burcelin, R., Serino, M., Chabo, C., Garidou, L., Pomié, C., Courtney, M., Amar, J., & Bouloumié, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12157 · Cited by 124
“Furthermore, statins, classical anti-dyslipidemic agents prescribed to reduce the incidence of cardiovascular events, are shown to be associated with microbial derived agents that could be responsible for the cholesterollowering effect, explaining the efficacy of the treatment [105].”
BackgroundBamberger, C., Rossmeier, A., Lechner, K., Wu, L., Waldmann, E., Fischer, S., Stark, R., Altenhofer, J., Henze, K., & Parhofer, K. (2018) · Nutrients · doi:10.3390/nu10020244 · Cited by 119
Gut Microbiome and Response to Cardiovascular Drugs
Tuteja, S., & Ferguson, J. F. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002314 · Cited by 134
Alphonse, P. A. S., & Jones, P. J. H. (2016) · Lipids · doi:10.1007/s11745-015-4096-7 · Cited by 116
“A clinical trial conducted in 944 individuals taking simvastatin at 40 mg/day for 6 weeks used a targeted gas chromatography–mass spectrometry metabolomics platform to measure a panel of metabolites within cholesterol synthesis, dietary sterol absorption, and bile acid formation [112].”
BackgroundMethodVillanueva-Millán, M. J., Pérez‐Matute, P., Recio‐Fernández, E., Rosales, J. M. L., & Oteo, J. A. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.21526 · Cited by 129
“Patients receiving statins were also excluded [18].”
Pharmacometabonomics in Humans: A New Tool for Personalized Medicine
Everett, J. R. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.20 · Cited by 117
Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine
Beger, R. D., Schmidt, M. A., & Kaddurah‐Daouk, R. (2020) · Metabolites · doi:10.3390/metabo10040129 · Cited by 117
“Genetic analysis of the patients identified associations between levels of several bile acids and a SNP in the gene encoding the organic anion transporter SLCO1B1 [19].”
BackgroundInfluentialSelf-citationMicrobiota–Host Transgenomic Metabolism, Bioactive Molecules from the Inside: Miniperspective
Turroni, S., Brigidi, P., Cavalli, A., & Candela, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00244 · Cited by 108
Novel Applications of Metabolomics in Personalized Medicine: A Mini-Review
Li, B., He, X., Jia, W., & Li, H. (2017) · Molecules · doi:10.3390/molecules22071173 · Cited by 104
“Simvastatin reducing plasma LDL-cholesterol GC/MS-based untargeted metabolomics LCA, TLCA, GLCA, COPR Increased in plasma of good-responders at baseline [24]”
MethodMetabolomics Reveals Amino Acids Contribute to Variation in Response to Simvastatin Treatment
Trupp, M., Zhu, H., Wikoff, W. R., Baillie, R. A., Zeng, Z.-B., Karp, P. D., Fiehn, O., Krauss, R. M., & Kaddurah-Daouk, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038386 · Cited by 99
“Using a second targeted metabolomics platform in participants from this study, secondary bile acids produced by the gut microbiome were found to be implicated in response to simvastatin [9].”
BackgroundInfluentialSelf-citationThe role of the gut microbiome in eye diseases
Zysset‐Burri, D. C., Morandi, S. C., Herzog, E. L., Berger, L., & Zinkernagel, M. S. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101117 · Cited by 113
Kantae, V., Krekels, E. H. J., van Esdonk, M. J., Lindenburg, P. W., Harms, A. C., Knibbe, C. A. J., van der Graaf, P. H., & Hankemeier, T. (2016) · Metabolomics · doi:10.1007/s11306-016-1143-1 · Cited by 100
Utilizing Probiotics for the Prevention and Treatment of Gastrointestinal Diseases
Milner, E., Stevens, B. D., An, M., Lam, V., Ainsworth, M., Dihle, P. J., Stearns, J., Dombrowski, A., Rego, D. T., & Segars, K. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.689958 · Cited by 103
“Interestingly, Lactobacillus metabolites have also been shown to compete for hepatic uptake of drugs such as simvastain, thereby altering the pharmacodynamics (Kaddurah-Daouk et al., 2011).”
BackgroundRyan, P. M., London, L. E. E., Bjorndahl, T. C., Mandal, R., Murphy, K., Fitzgerald, G. F., Shanahan, F., Ross, R. P., Wishart, D. S., Caplice, N. M., et al. (2017) · Microbiome · doi:10.1186/s40168-017-0246-x · Cited by 97
“Simvastatin is an example of a cardiovascular disease drug which modulates gut microbiota composition [63] and whose efficacy appears to rely on a suitably responsive microbiome [64].”
Gindin, M., Febvre, H. P., Rao, S., Wallace, T. C., & Weir, T. L. (2018) · Journal of the American College of Nutrition · doi:10.1080/07315724.2018.1483783 · Cited by 102
“Other exclusion criteria included recent antibiotic use (within 2 months of study enrollment) or the use of other medications that have been reported to alter the gut microbiota or inflammatory cytokines, including metformin (18), statins (19), and nonsteroidal antiinflammatory drugs (20).”
BackgroundMechanisms of gastrointestinal microflora on drug metabolism in clinical practice
Sun, C., Chen, L., & Shen, Z. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.09.011 · Cited by 97
The gut microbiome and hypertension
Pevsner‐Fischer, M., Blacher, E., Tatirovsky, E., Ben‐Dov, I. Z., & Elinav, E. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000293 · Cited by 93
Cometabolism of Microbes and Host: Implications for Drug Metabolism and Drug-Induced Toxicity
Li, H., & Jia, W. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.157 · Cited by 93
Hu, X., Li, H., Zhao, X., Zhou, R., Liu, H., Sun, Y., Fan, Y., Shi, Y., Qiao, S., Liu, S., et al. (2021) · Theranostics · doi:10.7150/thno.55946 · Cited by 101
“On the other hand, the composition of the host gut microbiota has also been revealed to influence the bioavailability of statins in vivo [24-27].”
BackgroundImpaired Plasmalogens in Patients with Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R., Zhu, H., K. Yao, J., Nimgaonkar, V. L., Buckley, P. F., Keshavan, M. S., Georgiades, A., & Nasrallah, H. A. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.019 · Cited by 89
Self-citationPharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
Sharma, A., Buschmann, M. M., & Gilbert, J. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1437 · Cited by 86
“Patients treated with simvastatin, a drug for hyperlipidemia, also benefit from indirect microbial impacts on drug availability.(58) Positive correlations have been observed between plasma concentrations of simvastatin and bacterial- derived primary and secondary bile acids, especially in good responders.”
BackgroundA Metabolomics Approach to Pharmacotherapy Personalization
Balashova, E. E., Maslov, D. L., & Lokhov, P. G. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8030028 · Cited by 79
A complex microworld in the gut: Gut microbiota and cardiovascular disease connectivity
Howitt, M. R., & Garrett, W. S. (2012) · Nature Medicine · doi:10.1038/nm.2895 · Cited by 78
Heterogeneity in statin responses explained by variation in the human gut microbiome
Wilmanski, T., Kornilov, S. A., Diener, C., Conomos, M. P., Lovejoy, J. C., Sebastiani, P., Orwoll, E. S., Hood, L., Price, N. D., Rappaport, N., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.007 · Cited by 72
Pharmacometabolomics Reveals Racial Differences in Response to Atenolol Treatment
Wikoff, W. R., Frye, R. F., Zhu, H., Gong, Y., Boyle, S., Churchill, E., Cooper-Dehoff, R. M., Beitelshees, A. L., Chapman, A. B., Fiehn, O., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057639 · Cited by 72
Self-citationPharmacometabonomics and personalized medicine
Everett, J. R., Loo, R. L., & Pullen, F. S. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213497929 · Cited by 75
“A third publication(75) used GC-TOF MS-based metabonomic and pharmacometabonomic analysis of extracted and derivatised plasma samples from the same patients reported previously.(73,74) Lower predose concentrations of xanthine, 2-hydroxyvaleric acid, succinic acid and stearic acid and higher predose concentrations of g…”
MethodGut bacterial microbiome composition and statin intake—A systematic review
Dias, A. M., Cordeiro, G., Estevinho, M. M., Veiga, R., Figueira, L., Reina‐Couto, M., & Magro, F. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.601 · Cited by 77
Pharmacometabolomics Reveals That Serotonin Is Implicated in Aspirin Response Variability
Ellero‐Simatos, S., Lewis, J. P., Georgiades, A., Yerges-Armstrong, L. M., Beitelshees, A., Horenstein, R. B., Dane, A. D., Harms, A. C., Ramaker, R., Vreeken, R. J., et al. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.22 · Cited by 74
Self-citationElucidation of Gut Microbiota-Associated Lipids Using LC-MS/MS and 16S rRNA Sequence Analyses
Yasuda, S., Okahashi, N., Tsugawa, H., Ogata, Y., Ikeda, K., Suda, W., Arai, H., Hattori, M., & Arita, M. (2020) · iScience · doi:10.1016/j.isci.2020.101841 · Cited by 76
Yerges-Armstrong, L. M., Ellero-Simatos, S., Georgiades, A., Zhu, H., Lewis, J. P., Horenstein, R. B., Beitelshees, A. L., Dane, A., Reijmers, T., Hankemeier, T., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.119 · Cited by 69
“(11-14) While these pharmacometabolomic studies have been successful in their own right, there has been additional success when this technology is harnessed to robust genomic methodologies using an approach coined pharmacometabolomic-informedpharmacogenomics.”
BackgroundSelf-citationBrunham, L. R., Baker, S. K., Mammen, A. L., Mancini, G. B. J., & Rosenson, R. S. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy119 · Cited by 75
Emergence of community behaviors in the gut microbiota upon drug treatment
García‐Santamarina, S., Kuhn, M., Devendran, S., Maier, L., Driessen, M., Mateus, A., Mastrorilli, E., Brochado, A. R., Savitski, M. M., Patil, K. R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.037 · Cited by 70
Bile acids at the cross-roads of gut microbiome–host cardiometabolic interactions
Ryan, P. M., Stanton, C., & Caplice, N. M. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0299-9 · Cited by 71
“Due to the individuality of our intestinal bacteria, some studies have already encountered complex multifactorial and personalized interactions between interventions and the gut microbiome, ultimately stratifying patients into responders and non-responders for some widely prescribed drug classes [138, 139].”
BackgroundA Comparison of Various Normalization Methods for LC/MS Metabolomics Data
Wulff, J. E., & Mitchell, M. W. (2018) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2018.98022 · Cited by 75
Pharmacometabonomics: data processing and statistical analysis
Fu, J., Zhang, Y., Liu, J., Lian, X., Tang, J., & Zhu, F. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab138 · Cited by 71
Tousoulis, D., Guzik, T. J., Padró, T., Duncker, D. J., Luca, G. D., Eringa, E. C., Vavlukis, M., Antonopoulos, A. S., Katsimichas, T., Cenko, E., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac057 · Cited by 75
“28 Indeed, many mechanisms have been proposed by which the GM can affect the bioavailability and actions of various cardiovascular drugs and how these drugs may affect the GM, although, to date, sufficient knowledge of these processes is still lacking.”
BackgroundThe Gut Microbiome, Metformin, and Aging
Induri, S. N. R., Kansara, P., Thomas, S. C., Xu, F., Saxena, D. B., & Li, X. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051920-093829 · Cited by 71
The influence of rosuvastatin on the gastrointestinal microbiota and host gene expression profiles
Nolan, J. A., Skuse, P., Govindarajan, K., Patterson, E., Konstantinidou, N., Casey, P. G., MacSharry, J., Shanahan, F., Stanton, C., Hill, C., et al. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00149.2016 · Cited by 68
Exploring the potential impact of probiotic use on drug metabolism and efficacy
Purdel, C. N., Ungurianu, A., Adam-Dima, I., & Margina, D. M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114468 · Cited by 71
Microbial Determinants of Biochemical Individuality and Their Impact on Toxicology and Pharmacology
Patterson, A. D., & Turnbaugh, P. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.002 · Cited by 66
“…(Firm), glucose (Glc), gut microbiota (GM), 3-hydroxy-3methyl-glutaryl-CoA reductase (HMGCR), lowdensity lipoprotein (LDL), primary bile acids (1 BA), secondary bile acids (2 BA), and taurob-muricholic acid (TbMCA). in LDL cholesterol-lowering efficacy (Kaddurah-Daouk et al., 2011) (Figure 3A).”
Ebrahim, Z., Proost, S., Tito, R. Y., Raes, J., Glorieux, G., Moosa, M. R., & Blaauw, R. (2022) · Nutrients · doi:10.3390/nu14040805 · Cited by 69
“Statins have been found to positively correlate with secondary gut-derived bile acids that contribute to the magnitude of LDL-lowering [71].”
Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches
Dhurjad, P., Dhavaliker, C., Gupta, K., & Sonti, R. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000669 · Cited by 66
Rosuvastatin alters the genetic composition of the human gut microbiome
Kummen, M., Solberg, O. G., Storm-Larsen, C., Holm, K., Ragnarsson, A., Trøseid, M., Vestad, B., Skårdal, R., Yndestad, A., Ueland, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-62261-y · Cited by 61
Drug–Exposome Interactions: The Next Frontier in Precision Medicine
Pristner, M., & Warth, B. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.012 · Cited by 62
Zhang, Q., Fan, X., Ye, R., Hu, Y., Zheng, T., Shi, R., Cheng, W., Lv, X., Chen, L., & Liang, P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00522 · Cited by 59
Rodríguez-Morató, J., & Matthan, N. R. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00863-7 · Cited by 57
Zwartjes, M., Gerdes, V. E. A., & Nieuwdorp, M. (2021) · Metabolites · doi:10.3390/metabo11080531 · Cited by 58
Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases
Rodrigues, S. G., der Merwe, V., Krag, A. A., & Wiest, R. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2023.101859 · Cited by 57
He, X., Zheng, N., Jiaojiao, H., Liu, C., Feng, J., Jia, W. P., & Li, H. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00984 · Cited by 56
Giacomini, K. M., Yee, S. W., Koleske, M. L., Zou, L., Matsson, P., Chen, E. C., Kroetz, D. L., Miller, M. A., Gozalpour, E., & Chu, X. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2627 · Cited by 46
“Interestingly, higher levels of several secondary bile acids in humans have been correlated with increased plasma concentrations of the cholesterol lowering drug, simvastatin.(88) These data suggest that secondary bile acids may decrease OATP1B1mediated simvastatin acid uptake in hepatocytes resulting in higher plasma…”
BackgroundPharmacometabolomics of Statin Response
Krauss, R. M., Zhu, H., & Kaddurah-Daouk, R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.164 · Cited by 49
Self-citationMiao, X., Xiao, B., Shui, S., Yang, J., Huang, R., & Dong, J.-X. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.01.028 · Cited by 51
Understanding and Modulating Mammalian-Microbial Communication for Improved Human Health
Mani, S., Boelsterli, U. A., & Redinbo, M. R. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140007 · Cited by 48
“An example of the importance of the enteric microbiome in the host drug response is seen with the cholesterol-lowering drug simvastatin (39).”
BackgroundExploring the role of gut microbiota in advancing personalized medicine
Huang, G., Khan, R., Zheng, Y., Lee, P.-C., Li, Q., & Khan, I. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1274925 · Cited by 50
“…rosuvastatin, and atorvastatin, several reports showed that GM could affect the drugs’ metabolism and absorption through bacterial-derived bile acids, but the specific bacteria and underlying mechanisms are still unknown (Kaddurah-Daouk et al., 2011; Nolan et al., 2017; Liu et al., 2018).”
BackgroundInterplays between drugs and the gut microbiome
Wan, Y., & Zuo, T. (2022) · Gastroenterology report · doi:10.1093/gastro/goac009 · Cited by 48
Microbiome and pancreatic cancer: time to think about chemotherapy
de Castilhos, J., Tillmanns, K., Blessing, J., Larano, A., Borisov, V., & Stein‐Thoeringer, C. K. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2374596 · Cited by 42
“111,112 Secondary bile acids, which are products of bacterial bile metabolism and modification, play a critical role in various diseases, including Clostridioides difficile infection, inflammatory bowel disease, metabolic diseases, 113 and cancer.”
BackgroundComparative analysis of the gut microbiota in distinct statin response patients in East China
Sun, B., Li, L., & Zhou, X. (2018) · The Journal of Microbiology · doi:10.1007/s12275-018-8152-x · Cited by 44
“Emerging studies have shown that the gut microbiota is linked to therapeutic responses to a variety of drugs, including statins (Moore, 2008; Kaddurahdaouk et al., 2011; Enright et al., 2016), through what is known as the microbiome-medicine interplay.”
BackgroundInvestigation of Host–Gut Microbiota Modulation of Therapeutic Outcome
Yip, L. Y., & Chan, E. C. Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063750 · Cited by 43
“The list of affected drugs is presented in Table 1 (Sousa et al., 2008; Clayton et al., 2009; Kaddurah-Daouk et al., 2011; Haiser and Turnbaugh, 2013; Saitta et al., 2014).”
InfluentialHuang, Q. B., Aa, J., Jia, H., Xin, X., Tao, C., Liu, L., Zou, B., Song, Q., Shi, J., Cao, B., et al. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00440 · Cited by 43
Andreassen, O. A., Desikan, R. S., Wang, Y., Thompson, W. K., Schork, A. J., Zuber, V., Doncheva, N. T., Ellinghaus, E., Albrecht, M., Mattingsdal, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123057 · Cited by 41
Gemikonakli, G., Mach, J., & Hilmer, S. N. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa047 · Cited by 44
Zysset‐Burri, D. C., Keller, I., Berger, L., Neyer, P. J., Steuer, C., Wolf, S., & Zinkernagel, M. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-51698-5 · Cited by 42
Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response
Trepka, K. R., Olson, C. A., Upadhyay, V., Zhang, C., & Turnbaugh, P. J. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022724-100847 · Cited by 36
“Several gut bacterial bile acid metabolites are associated with statin efficacy, potentially due to altered intestinal absorption of statins (37).”
Lazarević, S., Đanić, M., Al‐Salami, H., Mooranian, A., & Mikov, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879170 · Cited by 36
The Role of Gut Microbiota in the Etiopathogenesis of Multiple Chronic Diseases
Pires, L., Gonzaléz‐Paramás, A. M., Heleno, S. A., & Calhelha, R. C. (2024) · Antibiotics · doi:10.3390/antibiotics13050392 · Cited by 37
“Levels of primary and secondary BAs have been shown to influence the effectiveness of simvastatin in lowering LDL cholesterol [40].”
BackgroundPotential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability
Flowers, S. A., Bhat, S., & Lee, J. C. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2428 · Cited by 42
“Since bile acids and statins share transporters in the intestine, genetic analysis of the participants also identified associations between bile acid levels and a single nucleotide polymorphism, rs4149056, in the gene encoding the organic anion transporter SLCO1B1.(33) These findings indicate that interactions between…”
BackgroundInfluentialImpact of the Gut Microbiota on Atorvastatin Mediated Effects on Blood Lipids
Zimmermann, F., Roessler, J., Schmidt, D., Jasina, A., Schumann, P., Gast, M., Poller, W. C., Leistner, D. M., Giral, H., Kränkel, N., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051596 · Cited by 36
“Another metabolic pathway that may link the gut microbiome with the magnitude of statin effect are secondary bile acids [18].”
BackgroundZhu, X., Li, Y., Jiang, Y., Zhang, J., Duan, R., Liu, L., Liu, C., Xu, X., Yu, L., Wang, Q., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.665406 · Cited by 32
GUT Microbiome-GUT Dysbiosis-Arterial Hypertension: New Horizons
Katsi, V. K., Didagelos, M., Skevofilax, S., Armenis, I., Kartalis, A. N., Vlachopoulos, C. V., Karvounis, H. I., & Tousoulis, D. M. (2018) · Current Hypertension Reviews · doi:10.2174/1573402114666180613080439 · Cited by 32
Relation of Statin Use to Gut Microbial Trimethylamine N-Oxide and Cardiovascular Risk
Li, D. Y., Li, X. S., Chaikijurajai, T., Li, L., Wang, Z., Hazen, S. L., & Tang, W. H. W. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.05.010 · Cited by 34
Metadata
- Authors
- Kaddurah-Daouk, R., Baillie, R. A., Zhu, H., Zeng, Z.-B., Wiest, M. M., Nguyen, U. T., Wojnoonski, K., Watkins, S. M., Trupp, M., & Krauss, R. M.
- Affiliations
- Duke Medical Center (US)
- Rosa (United States) (US)
- North Carolina State University (US)
- University of Idaho (US)
- SRI International (US)
- Corresponding author
- Kaddurah-Daouk, Rima
- Krauss, Ronald M.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-10-13
- Volume
- 6
- Issue
- 10
- Pages
- e25482
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3192752
- OpenAlex
- W1998108632
- Cited by
- 193
- References
- 44
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 15 · 2023: 12 · 2022: 13 · 2021: 16 · 2020: 19 · 2019: 12 · 2018: 19 · 2017: 13 · 2016: 14 · 2015: 12 · 2014: 8 · 2013: 17 · 2012: 9
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Update notices
- correction (2013-05-06)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Washington
- National Heart, Lung, and Blood Institute (U01HL069757)
- National Institute of General Medical Sciences (GM078233, R24GM078233)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- simvastatin, LDL cholesterol lowering, gut microbiota metabolites, secondary bile acids, cholesterol biosynthesis, bile acid transporters, SLCO1B1, rs4149056, pharmacogenetics, metabolomics, personalized treatment, cardiovascular disease
- MeSH terms
- Bile Acids and Salts, Demography, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Models, Biological, Pharmacogenetics, Treatment Outcome, Simvastatin, Polymorphism, Single Nucleotide, Organic Anion Transporters, Liver-Specific Organic Anion Transporter 1, Gastrointestinal Tract, Metagenome, Metabolomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.